High-Value Federal Grants ($5M+) — February 24, 2026

Two small biotechs secured $209M total obligations for anti-infectives and Marburg virus immunotherapy, with $98M+ outlayed and options to $397M through 2036.

$94M firm-fixed price award to veteran-owned firm for disability exams, with 11% ($10M) outlayed despite ended base period.

$175M obligation from 2005 with $0 outlay and ended 2020 performance raises doubts on value realization.

Low outlays vs obligations: $0/$175M (QLARANT), $54M/$111M (MAPP), $45M/$98M (Medicines), $10M/$94M (VES); ended periods for two contracts signal potential funding halts.

Full/open competition wins by small/veteran-owned firms may intensify as BARDA/VA prioritize set-asides in future rounds.

BARDA options could unlock $188M+ additional funding ($299M MAPP + $98M Medicines base/options)

Recurring HHS/VA awards to small/veteran-owned firms in biodefense and disability services point to sustained federal healthcare outsourcing.

BARDA's $209M+ commitments to small biotechs for anti-infectives/Marburg signal heavy HHS focus on long-duration (to 2036) infectious disease programs.

Pre-2021 awards (QLARANT, VES) show $0-11% outlays despite high obligations, contrasting active BARDA funding.

{"entity"=>"MAPP Biopharmaceutical", "reason"=>"$111M obligated with $189M options to 2036; highest growth potential in Marburg R&D.", "trigger"=>"Option exercise >$50M or outlay acceleration"}

{"entity"=>"BARDA Solicitations", "reason"=>"Cluster of biotech wins indicates pipeline for biodefense funding.", "trigger"=>"New awards >$50M in NAICS 54171X"}

{"entity"=>"QLARANT Integrity Solutions", "reason"=>"$175M dormant obligation risks write-down but flags CMS follow-on potential.", "trigger"=>"Outlay activity or new CMS data processing awards"}